New Mexico Administrative Code
Title 16 - OCCUPATIONAL AND PROFESSIONAL LICENSING
Chapter 19 - PHARMACISTS
Part 26 - PHARMACIST PRESCRIPTIVE AUTHORITY
Section 16.19.26.12 - NALOXONE FOR OPIOID OVERDOSE
Universal Citation: 16 NM Admin Code 16.19.26.12
Current through Register Vol. 35, No. 18, September 24, 2024
A. Protocol:
(1) Prescriptive
authority for naloxone drug therapy shall be exercised solely in accordance
with the written protocol for naloxone drug therapy approved by the
board.
(2) Any pharmacist
exercising prescriptive authority for naloxone drug therapy must maintain a
current copy of the written protocol for naloxone drug therapy approved by the
board.
B. Education and training:
(1) The
pharmacist must successfully complete a course of training, accredited by the
accreditation council for pharmacy education (ACPE), in the subject area of
naloxone for opioid overdose drug therapy provided by:
(a) the New Mexico pharmacists association;
or
(b) a similar health authority
or professional body approved by the board.
(2) Training must include study materials and
instruction in the following content areas:
(a) mechanisms of action;
(b) contraindications;
(c) identifying indications for the use of
naloxone drug therapy;
(d) patient
screening criteria;
(e) counseling
and training patient and care-giver regarding the safety, efficacy and
potential adverse effects of naloxone;
(f) evaluating patient's medical profile for
drug interactions;
(g) referring
patient for follow-up care with primary healthcare provider;
(h) informed consent;
(i) record management;
(j) management of adverse events.
(3) Continuing education: Any
pharmacist exercising prescriptive authority for naloxone drug therapy shall
complete a minimum of 0.2 CEU of live ACPE approved naloxone drug therapy
related continuing education every two years. Such continuing education shall
be in addition to requirements in
16.19.4.10
NMAC.
C. Authorized drug(s):
(1)
Prescriptive authority shall be limited to naloxone and shall include any
device(s) approved for the administration of naloxone.
(2) Prescriptive authority for naloxone drug
therapy shall be limited to naloxone as delineated in the written protocol for
naloxone drug therapy approved by the board.
D. Records:
(1) The prescribing pharmacist must generate
a written or electronic prescription for any naloxone dispensed.
(2) Informed consent must be documented in
accordance with the approved protocol for naloxone drug therapy and a record of
such consent maintained in the pharmacy for a period of at least three
years.
E. Notification: Upon signed consent of the patient, the pharmacist shall notify the patient's designated physician or primary care provider within 15 days of naloxone dispensing.
Disclaimer: These regulations may not be the most recent version. New Mexico may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
